ProQR Announces Positive Top-Line Results from a Phase 1b Study of QR-010 in Subjects with Cystic Fibrosis Press release … intends to target these mutations using its proprietary Axiomer ® technology, which has shown compelling data in … septembre 25, 2017
ProQR Reports Fourth Quarter and Full Year 2018 Operating and Financial Results Press release LEIDEN, The Netherlands & CAMBRIDGE, Mass., Feb. 27, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. février 27, 2019